RecruitingPhase 3NCT06716281

Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis


Sponsor

Shanghai IxCell Biotechnology Co., LTD

Enrollment

398 participants

Start Date

Jan 5, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

To evaluate the efficacy of IxCell hUC-MSC-O in the treatment of patients with knee osteoarthritis. To evaluate the safety of IxCell hUC-MSC-O in the treatment of patients with knee osteoarthritis.


Eligibility

Min Age: 40 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Human umbilical cord mesenchymal stem cells and a biological treatment called Placebo for people with knee osteoarthritis. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALHuman umbilical cord mesenchymal stem cells

a single intra-articular injection of IxCell hUC-MSC-O at a dose of 5.0×10\^7 cells with a volume of 2.0 mL

BIOLOGICALPlacebo

Sodium Chloride Injection


Locations(1)

The Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06716281


Related Trials